About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Loads of shares!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Mathematically, just a thought.

I'm following this cy which is now sell 0.02p buy 0.02p.
On first thought, as long as it doesn't go bust, then the sp can't go lower!

However, how can it go higher? If MM rise it higher, eg sell 0.03p then it might not look much but in fact everybody makes a cool 50% profit.

As I can't see this happening particularly in current climate presumably sp won't move, for ever!

dealerdear

I think it goes up in percentages to .0003 not just .0002 or .0003 when you deal it thats when you find out the price.

Im for 200 you properly get 150 if you sold them.

Just done a dummy 1m shares for 190.

I cant do a dummy on the sell I havent got any.

Thanks driver.

Just done a dummy as well, or perhaps I am the dummy!

Driver ... How low can this Go !!! IF pothead/canoncan is still around I bet he'S in the RED !!

EIRX THERAPEUTICS PLC

('EiRx' or 'the Company')

Update on medicinal chemistry collaboration with University College Cork

Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to update shareholders on the progress of its Innovation Partnership collaboration with Professor Anita Maguire, Chair of Pharmaceutical Chemistry at University College Cork ('UCC'), Ireland.

As previously announced, the parties entered the collaboration to establish a medicinal chemistry team in Cork, working under the supervision of Professor Maguire to optimise compounds emerging from the Company's EnPADTM drug discovery platform and advance them towards clinical trials. The refinancing undertaken by the Company in February 2008 enabled the Company to meet its financial obligations under the collaboration, and thus to begin the process of recruitment and initiation of the project. The Company is pleased to advise that the technical research programme has begun following a rigorous recruitment process resulting in the appointment of two experienced chemists, Mr Andrew Osnowski and Dr Nicolas Brondel.




Andrew Osnowski brings to the EiRx / UCC collaborative team a decade of experience in the chemical optimisation of new drug candidates, earned in the commercial environment. Most recently he was Medicinal Chemistry Team Leader at Scottish Biomedical, where he was responsible for the management of research teams engaged in the contracted development of new pharmaceutical agents for an international roster of commercial clients. During this time teams under his management successful advanced a number of client projects from hit compounds through to optimised 'drug-like' products. Prior to his four years with Scottish Biomedical, Mr Osnowski held a series of research chemist positions in biotechnology and pharmaceutical companies, including two years in the medicinal chemistry team at Cyclacel Pharmaceuticals, a developer of kinase inhibitor drugs for the treatment of cancer. He holds a first-class honours degree in Chemistry from the University of Strathclyde.




Dr Nicolas Brondel comes to the EiRx / UCC partnership from a post-doctoral research position at UCC, where he spent two years investigated the role of the sulphur atom on the solid state structure of pharmaceutical compounds. He gained his PhD in Organic Chemistry from the Universitde Poitiers, France, for work on the synthesis of phosphatase inhibitor compounds with potential anticancer utility. His considerable expertise in pharmaceutical synthetic chemistry is expected to have a decisive influence on the success of the Innovation Partnership programme.




Commenting on developments in the Innovation Partnership programme, Dr Colin Telfer, Chief Executive Officer of EiRx, said: 'We are delighted to have attracted two such experienced chemists to the project, and to see work begin in our collaborator Professor Maguire's state-of-the-art laboratories. The combining of medicinal chemistry expertise with our EnPADTM cellular screening platform technology is a watershed moment for EiRx, as an effective drug discovery engine requires both elements of biology and chemistry. We are already feeling the benefit our medicinal chemists' input into our product development effort, and have high expectations for the programme over the two years of the partnership project.'

sp now in the uptrend.. time to start buying

I dont think so !! Not For me ;)

EiRx Therapeutic shares suspended on AIM; says bankers have withdrawn support
AFX


LONDON (Thomson Financial) - EiRx Therapeutics Plc. said Tuesday it has requested a suspension of trading in its shares on AIM pending clarification of its financial position.

It said its bankers have declined to provide the replacement 350,000-pound facility despite Billam AG having agreed to extend its guarantee to 350,000 pounds.

EiRx said as it has paid back 200,000 pounds, it is facing a 'substantial' shortfall of 350,000 pounds and cannot say if it will be able to secure alternative funding before September, when the 300,000-pound loan facility from Billam becomes available.

It, however, added that with Billiam's help it is seeking to put replacement funding in place.





Not looking too Good !

Thank you very much and goodnight.
Last one close the door.

Looking a bit sad, I did say when I got out (at a loss) so dont blame me

Maybe their IP is worth 10p a share, nice liquidation proceeds on the way.............................watch out, there's another flying pig!!

Sorry for losers here all except potatohead.

Deserves what he gets and I hope he is mashed.

Bloody pump and dumper.

RNS Number : 7588B
EiRx Therapeutics PLC
20 August 2008



Eirx Therapeutics plc ('the Company')




Resignation of Director, Liquidation of subsidiary




Eirx Therapeutics plc announced today that it is applying to put its wholly owned Irish subsidiary Eirx Therapeutics Limited.('ETL') into liquidation. Michael McAteer of Foster McAteer, Chartered Accountants, Dublin has been asked to allow his name to go forward for appointment as liquidator of ETL.




Colin Telfer the CEO has been made redundant as part of the liquidation process, and has resigned as a director of the Company effective 19 August 2008. The board of EiRx would like to express its gratitude to Dr Telfer for all his efforts on behalf of the Company. John Pool, Nick Strong and Tom Cotter remain as directors.




The directors of Eirx Therapeutics plc are working to put together a plan designed to secure the future of the Company based around its other operating business, Auvation Limited. Further announcements will be made as appropriate.

A sad end by the looks of it.

"EIRX PLOTS RETURN WITH A 15M LISTING

The fundraising will allow EiRx to invest in up to nine companies

Monday March 28,2011
By Andrew Johnson

Comment Speech Bubble Have your say(0)

LIFE sciences specialist EiRx Therapeutics is plotting a return to Aim after being forced to de-list more than two years ago.

It is hoping to raise 15million in the move, which should go ahead in June and is expected to value the company at about 50million.

EiRx was compelled to leave Aim after the Bank of Scotland pulled promised funding in 2008 during the financial crisis.

Chairman John Pool says the plan is to create a specialist life sciences investment and management business aimed at mitigating the risks associated with early-stage companies in the sector.

The fundraising will allow EiRx to invest in up to nine companies in two main areas anti-infectives and cancer treatments.

Some are already generating revenues, one is close to signing an agreement with a big German medical devices group thought to be Bayer while others are seeking funding for clinical trials.

EiRx is currently seeking 920,000 in a pre-float fundraising to conduct due diligence and back the move onto Aim.

The money raised in the float will also allow EiRx to continue to invest in its businesses without having to constantly seek further funds.

In the future, the company hopes to expand into other areas, such as cardiovascular treatments.

The proposed chief executive is Kris Matykiewicz, formerly of AstraZeneca, while non-executives include Professor Andrew Porter, of the University of Aberdeen, and AstraZeneca director of safety science, Dr John Pears.

http://www.express.co.uk/posts/view/237200/EiRx-plots-return-with-a-15m-listing

Have you subscribed Driver? For old times sake I've put down all of 180. :o)

kim

No i sold all my ERX before it went tits up will be watching with interest.

amoeba bio companies have an exceptionally high mortality rate